Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

Item
http://www.wikidata.org/entity/Q34502042
Down-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemiaEfficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaAssociation between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemiaGPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndromeEpigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia.Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemiaEpigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.Prevalence and Prognostic Impact of CEBPA Gene Mutation (Simplified Assay Technique) in Egyptian Acute Myeloid Leukemia Patients with Normal Cytogenetics.High bone marrow ID2 expression predicts poor chemotherapy response and prognosis in acute myeloid leukemia.Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia.H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia.Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies.GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemiaOverexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia
P2860

Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

Item
http://www.wikidata.org/entity/Q34502042
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@ast
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@en
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@nl
type
label
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@ast
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@en
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@nl
prefLabel
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@ast
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@en
Double CEBPA mutations are pro ...... h wild-type NPM1 and FLT3-ITD.
@nl
P1433
P1476
P2093
P2860
P304
P31
P433
P478
P577
P698
P921
P932
P1433
P1476
Double CEBPA mutations are pro ...... th wild-type NPM1 and FLT3-ITD
@en
P2093
P2860
P304
P31
P433
P478
P577
P698
P921
P932